The Trial in Progress poster includes an overview and study design of the TACTI-004 Phase III evaluating the Company’s MHC Class II agonist, eftilagimod alfa (efti) in combination with MSD’s (Merck & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback